Therapeutic delivery of miR-200c may provide personalized treatment for patients with the molecular subtype of PCa that harbors TMPRSS2-ERG gene fusions..     ///    TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c.. 